Paratek investor relations
WebParatek Pharma Email Alerts Investor Relations Investor Overview Corporate Governance Stock Information SEC Filings News Information Request RSS - SEC Filings RSS - Events … Web10 Apr 2024 · Investor Relations GlobeNewswire Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical ...
Paratek investor relations
Did you know?
Web25 Jul 2024 · The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial 877-300-8521 and international investors should dial +1-412-317-6026. The conference ID is 10169245. Web3 Aug 2024 · Investor Relations: Hans Vitzthum LifeSci Advisors [email protected] Phone: 617-430-7578 Media: Christine Fanelle Scient PR [email protected] Phone: …
WebAdam Woodrow President and Chief Commercial Officer William Haskel Chief Legal Officer, General Counsel and Corporate Secretary Randy Brenner Chief Development and … WebInvestor Relations Careers Overview Learn More. The Team. Testimonials; More >> Positions Available. ... He previously served on the board of Transcept Pharmaceuticals, Inc. from April 2013 until its merger with Paratek on October 30, 2014. Previously, Dr. Dietz was a member of the research faculty in the Department of Medicine, University of ...
WebThese are our priorities at Paratek Pharmaceuticals. We develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe … Web3 Nov 2024 · Investor Relations: Hans Vitzthum LifeSci Advisors [email protected] Phone: 617-430-7578. Media: Christine Fanelle Scient PR [email protected] Phone: …
Web16 Mar 2024 · Paratek routinely posts important information for investors on the Investor Relations section of its website at www.ParatekPharma.com. Paratek intends to use this website as a means of...
Web26 Apr 2024 · Domestic investors wishing to participate in the call should dial: 877-300-8521 and international investors should dial: +1-412-317-6026. The conference ID is 10166263. Investors can also... chesapeake orthopaedicWeb3 Jan 2024 · Paratek Pharmaceuticals' enterprise value of $369 million is less than 2X 2024 sales. ... Our analysts are third party authors that include both professional investors and individual investors who ... flights zimbabwe to londonWeb9 Aug 2024 · Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2024 Paratek Pharmaceuticals August 9, 2024, 1:05 PM · 11 min read -- NUZYRA® (omadacycline) Generated Net... flights zih phxWeb9 Aug 2024 · Paratek reported net income of $9.7 million, or $0.20 per share, for the second quarter of 2024, compared to a net loss of $23.1 million, or ($0.53) per share, for the same … chesapeake orthopaedic sports medicineWebBOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and … flights zqnWeb27 Feb 2024 · Investor Relations EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. chesapeake orthodontistWeb4 May 2024 · Paratek Pharmaceuticals Announces First Quarter 2024 Revenue of $24.9 Million Paratek Pharmaceuticals May 4, 2024, 4:05 PM · 10 min read Paratek Pharmaceuticals -- NUZYRA® (omadacycline)... flights zih pdx